Comparison of effectiveness of Ropivacaine in combination with Nalbuphine, Clonidine, Dexmedetomidine in Epidural anaesthesia in lower limb surgery

A comparative study of nalbuphine, clonidine and dexmedetomidine as an adjuvant to ropivacaine in epidural anaesthesia in lower limb surgery. - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/02/062736

Enrollment

Registered

2024-02-16

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S729- Unspecified fracture of femur Health Condition 2: S829- Unspecified fracture of lower leg Health Condition 3: S999- Unspecified injury of ankle and foot Health Condition 4: S989- Traumatic amputation of foot, level unspecified Health Condition 5: S878- Crushing injury of lower leg Health Condition 6: S720- Fracture of head and neck of femur Health Condition 7: S721- Pertrochanteric fracture Health Condition 8: S722- Subtrochanteric fracture of femur Health Condition 9:

Interventions

Intervention1: Dexmedetomidine as an adjuvant to Ropivacaine in Epidural anaesthesia: This group will receive 15ml of 0.75% Ropivacaine plus injection Dexmedetomidine 1.5 microgram/kg plus Normal sali

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients with ASA grade I and II. 2. Patients with body mass index between 18-30 kg/m2. 3. Patients of either sex posted for lower limb orthopaedic surgery.

Exclusion criteria

Exclusion criteria: 1. Coagulopathy/thrombocytopenia. 2. Localized infection at the proposed site of injection. 3. Inability to comprehend the scoring systems to be employed due to physical or mental problems. 4. Known allergy to the drugs to be used (local anesthetics, opioids). 5. Opioid tolerance/dependence. 6. Renal/hepatic impairment. 7. Known cardio respiratory impairment. 8. Patient with any neurological disorder. 9. Known contraindication to epidural anesthesia. 10. Pregnant woman and breastfeeding woman.

Design outcomes

Primary

Measure	Time frame
1. Onset & duration of sensory and motor blockade. 2. Duration of analgesia.Timepoint: up to 24 hours.	—

Secondary

Measure	Time frame
1. Hemodynamic changes like heart rate, blood pressure, saturation, respiratory rate. 2. Sedation 3. Patient’s satisfaction score. 4. Side effects if any.Timepoint: up to 24 hours.	—

Countries

India

Contacts

Public ContactDr Deepanshu Panchal

Uttar Pradesh University Of Medical Sciences Saifai Etawah

ushashukla1970@gmail.com9412201915

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026